Metagenomi Therapeutics (MGX) Amortizatization of Intangibles (2023 - 2026)
Metagenomi Therapeutics (MGX) reported Amortizatization of Intangibles of $360000.0 for Q1 2026, down 64.25% year-over-year from $1.0 million in Q1 2025, and down 23.4% quarter-over-quarter from $470000.0 in Q4 2025.
Metagenomi Therapeutics (MGX) Amortizatization of Intangibles (2023 - 2026) Analysis & Trends
Metagenomi Therapeutics (MGX) has 4 years of Amortizatization of Intangibles data on file, last reported at $360000.0 in Q1 2026.
- Amortizatization of Intangibles for Q1 2026 came in at $360000.0, down 64.25% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.4 million (down 60.49% YoY), and the FY2025 annual result was $3.0 million, down 51.37% from the prior year.
- Amortizatization of Intangibles retreated to $360000.0 in Q1 2026 per MGX's latest filing, from $470000.0 in the prior quarter.
- Over five years, Amortizatization of Intangibles peaked at $2.4 million in Q2 2023 and troughed at $360000.0 in Q1 2026.
- A 4-year average of $1.4 million and a median of $1.3 million in 2024 frame the typical range for Amortizatization of Intangibles.
- The sharpest annual moves came in 2024 and 2025: Amortizatization of Intangibles slipped 16.84% in 2024, then sank 64.98% in 2025.
- A 4-year view of Amortizatization of Intangibles shows it stood at $1.6 million in 2023, then slipped by 17.16% to $1.3 million in 2024, then slumped by 64.98% to $470000.0 in 2025, then fell by 23.4% to $360000.0 in 2026.
- Business Quant data shows MGX's Amortizatization of Intangibles at $360000.0 in Q1 2026, $470000.0 in Q4 2025, and $705000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 821,726.73 Bn | 821,726.69 Bn | - | - |
| 2 | Belite Bio | 57,768.00 Bn | 57,768.00 Bn | - | - |
| 3 | Quantum Biopharma | 16,655.88 Bn | 16,655.88 Bn | - | 13,267.00 |
| 4 | Legend Biotech | 3,540.00 Bn | 3,539.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,526.26 Bn | 1,526.24 Bn | - | - |
| 6 | Akari Therapeutics | 1,520.09 Bn | 1,520.09 Bn | - | - |
| 7 | Psyence Biomedical | 223.87 Bn | 223.87 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.47 Bn | 107.23 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.22 Bn | 91.22 Bn | - | - |
| 10 | Metagenomi Therapeutics | 42.84 Mn | 42.84 Mn | - | 360,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 360,000.00 |
| Mar 31, 2026 | 360,000.00 |
| Dec 31, 2025 | 470,000.00 |
| Dec 31, 2025 | 470,000.00 |
| Sep 30, 2025 | 705,000.00 |
| Sep 30, 2025 | 705,000.00 |
| Jun 30, 2025 | 818,000.00 |
| Jun 30, 2025 | 818,000.00 |
| Mar 31, 2025 | 1.01 Mn |
| Mar 31, 2025 | 1.01 Mn |
| Dec 31, 2024 | 1.34 Mn |
| Dec 31, 2024 | 1.34 Mn |
| Sep 30, 2024 | 1.63 Mn |
| Sep 30, 2024 | 1.63 Mn |
| Jun 30, 2024 | 1.98 Mn |
| Jun 30, 2024 | 1.98 Mn |
| Mar 31, 2024 | 1.22 Mn |
| Mar 31, 2024 | 1.22 Mn |
| Dec 31, 2023 | 1.62 Mn |
| Dec 31, 2023 | 1.62 Mn |